Is Journal of Biological Chemistry a Good Journal? The ASBMB Biochemistry Workhorse

This is underappreciated. JBC charges nothing to publish. In a landscape where Molecular Cell, EMBO Journal, and Nature Communications charge $3,000-5,000+ in APCs or are behind society paywalls, JBC's free publication pathway is a genuine financial advantage, especially for labs without large APC budgets.

For early-career researchers, postdocs, and labs in countries with limited funding, JBC's zero-cost model means rigorous mechanistic biochemistry can get published without a budget decision.

Here's the honest career question: should you publish in JBC at IF 4.0, or aim higher?

If the paper is strong enough for Molecular Cell or EMBO Journal, aim higher first. JBC will still be there if those journals say no, and the IF gap is substantial.

If the paper is solid mechanistic biochemistry (rigorous, complete, publishable) but not a conceptual breakthrough, JBC is exactly right. The readership is biochemists. The editorial evaluation is by ASBMB members who understand the science. The publication is free. And in biochemistry departments, a JBC paper still means something that an equivalent paper in a generic open-access journal doesn't.

The worst decision is avoiding JBC because of IF anxiety and submitting to a journal whose readership doesn't include biochemists. A JBC paper that reaches the right 5,000 people matters more than a higher-IF paper that reaches no one in your field.

Before submitting, a JBC mechanistic story completeness check can assess whether the mechanistic story is complete enough for JBC's editorial standards.

JBC (ASBMB, IF ~4.8) became fully gold open access in January 2021. The entire 115-year archive is free to read. For ASBMB members, publication is $0. For non-members, the APC is approximately $2,500. This makes JBC one of the most cost-effective venues in biochemistry.

JBC publishes research elucidating the molecular and cellular basis of biological processes, biochemistry, chemical biology, biophysics, systems biology, RNA biology, immunology, microbiology, and neurobiology. The journal also welcomes methods papers that will be useful to the research community.

JBC does not accept purely descriptive studies without mechanistic insight. It also does not publish clinical research without a biochemical mechanism.

A JBC scope and mechanistic evidence check can score desk-reject risk before you submit.

In our pre-submission review work with manuscripts targeting Journal of Biological Chemistry, three patterns generate the most consistent desk rejections among the papers we analyze.

Mechanistic claims not supported by direct biochemical evidence. JBC's author guidelines state explicitly that the journal publishes research "elucidating the molecular and cellular basis of biological processes" with an emphasis on mechanism. We observe that papers frequently make mechanism claims based on correlational or phenotypic data without the biochemical assays that establish cause. A paper showing that a protein knockout changes cell behavior is not a JBC paper unless it also demonstrates the molecular mechanism: binding affinity, catalytic activity, structural interaction, or pathway biochemistry. Reviewers return papers at the revision stage asking for mechanism data that should have been included before submission.

Incomplete characterization of enzyme kinetics or binding parameters. When a paper involves enzymatic activity or protein-ligand interaction, JBC reviewers apply the community standard for kinetic reporting: Km, kcat, Ki values with proper error analysis, and temperature and buffer conditions specified. We see papers where kinetic constants are reported from single-concentration assays, or where IC50 values substitute for Ki measurements without explanation. The ASBMB community sets a high bar for quantitative biochemistry, and incomplete parameter reporting triggers mandatory revisions that could have been avoided.

Phenotypic studies presented as biochemistry papers. JBC does not publish clinical research without a biochemical mechanism, and we see authors attempt to reframe phenotypic cell biology or in vivo studies as biochemistry by adding a protein interaction experiment or a pulldown assay. The editorial team identifies this mismatch quickly because the JBC scope requires mechanism to be the primary contribution, not a supporting experiment. Papers where the main figures are phenotypic and the biochemistry is supplemental are redirected to cell biology journals.

SciRev author-reported data confirms JBC's 5-7 week median to first decision. A JBC mechanistic story and biochemical evidence check can verify whether your mechanistic story, kinetic characterization, and biochemical evidence package meet JBC's editorial standard before submission.